EFEKTIVITAS PENGGUNAAN KORTIKOSTEROID TERHADAPPASIEN COVID-19 DERAJAT BERAT DENGAN ARDS: Tinjauan Sistematik
Introduction: ARDS is a major complication of COVID-19 infection and is associated with a high mortality rate. Currently, no definitive therapy has been shown to reduce ARDS-related mortality with either COVID-19 or non-COVID-19 etiology. The mechanism COVID-19 progresses to ARDS is thought to be du...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
2022-01-12.
|
| Subjects: | |
| Online Access: | Link Metadata |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | repoupnvj_16420 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Soraya Maulidina, . |e author |
| 245 | 0 | 0 | |a EFEKTIVITAS PENGGUNAAN KORTIKOSTEROID TERHADAPPASIEN COVID-19 DERAJAT BERAT DENGAN ARDS: Tinjauan Sistematik |
| 260 | |c 2022-01-12. | ||
| 500 | |a http://repository.upnvj.ac.id/16420/1/ABSTRAK.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16420/13/AWAL.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16420/2/BAB%201.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16420/4/BAB%202.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16420/6/BAB%203.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16420/5/BAB%204.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16420/7/BAB%205.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16420/8/DAFTAR%20PUSTAKA.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16420/9/RIWAYAT%20HIDUP.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16420/11/LAMPIRAN.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16420/12/HASIL%20PLAGIARISME.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16420/10/ARTIKEL%20KI.pdf | ||
| 520 | |a Introduction: ARDS is a major complication of COVID-19 infection and is associated with a high mortality rate. Currently, no definitive therapy has been shown to reduce ARDS-related mortality with either COVID-19 or non-COVID-19 etiology. The mechanism COVID-19 progresses to ARDS is thought to be due to a cytokine storm. The anti-inflammatory effect of corticosteroids may reduce pulmonary and systemic hyperinflammation due to increased secretion of proinflammatory cytokines. This systematic review will review the effectiveness of using corticosteroids in severe COVID-19 patients with ARDS. Method: A systematic review was conducted by searching the literature on Pubmed and Google Scholar databases with reference to the PRISMA-P method. The literature obtained was then selected through the JBI Critical Appraisal Checklist. Results: administration of corticosteroids with low-high doses of IV methylprednisolone 0.6 - 8 mg/kg/day or high doses of IV dexamethasone 10 - 20 mg/day for 10 days during the early phase of ARDS or risk of developing ARDS (clinical worsening >7 days of onset symptoms) or >72 hours of hospitalization yielded beneficial outcomes in severe COVID-19 patients with ARDS. Corticosteroids were associated with a decreased blood CRP levels, improved ventilation and oxygenation, but did not reduced the risk of mortality and decrease the duration of hospitalization. Conclusion: the use of corticosteroids helps to provide beneficial outcomes in severe COVID-19 patients with ARDS | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 690 | |a R Medicine (General) | ||
| 690 | |a RM Therapeutics. Pharmacology | ||
| 655 | 7 | |a Thesis |2 local | |
| 655 | 7 | |a NonPeerReviewed |2 local | |
| 787 | 0 | |n http://repository.upnvj.ac.id/16420/ | |
| 787 | 0 | |n http://repository.upnvj.ac.id | |
| 856 | 4 | 1 | |u http://repository.upnvj.ac.id/16420/ |z Link Metadata |